---
schema_version: "secwatch.filing_event.v1"
accession: "0001679363-23-000074"
form_type: "8-K"
ticker: null
cik: "0001679363"
company_name: "Morphic Holding, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:32:46.526686+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Morphic Q3 net loss $36.2M; CEO on medical leave; positive MORF-057 Phase 2a data

## Summary
- Net loss of $36.2M ($0.73/share) vs net income $30.0M ($0.78/share) a year ago; revenue $0.
- President Bruce Rogers appointed interim principal executive officer as CEO Praveen Tipirneni remains on medical leave.
- Positive EMERALD-1 Phase 2a data: MORF-057 achieved primary endpoint (RHI reduction 6.4 points, p=0.0019); mMCS remission 25.7% at week 12.
- Cash, equivalents, and marketable securities $725.1M, providing runway into H2 2027.
- EMERALD-2 Phase 2b enrollment on track; Phase 2b for Crohn's disease expected to begin H1 2024.

## SEC filing metadata
- accession: 0001679363-23-000074
- form_type: 8-K
- cik: 0001679363
- company_name: Morphic Holding, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/morf-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001679363-23-000074
- JSON: https://secwatch.observer/filing/0001679363-23-000074.json
- Plain text: https://secwatch.observer/filing/0001679363-23-000074.txt

## Key facts
- Earnings Releases
  Morphic Holding, Inc. reported the third quarter 2023 results: revenue $0 million, net income $36.2 million, EPS $0.73 per share.
  - Period: the third quarter 2023
  - Revenue: $0 million
  - Net income: $36.2 million
  - EPS: $0.73 per share
  - Result: reported results
  source text: quarter ended September 30, 2023, was $36.2 million or $0.73 per share compared to net income of $30.0 million or $0.78 per share for the same quarter last year • Revenue was $0 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter last year due to the conclusion of the Company’s research and development collaborations
  evidence_url: https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm
- Executive change
  Bruce N. Rogers was appointed as interim principal executive officer at Morphic Holding, Inc..
  - Action: appointed
  - Role: interim principal executive officer
  source text: the Board has appointed Bruce N. Rogers, Ph.D., the Company’s President, as the Company’s interim principal executive officer until Dr. Tipirneni’s return.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm
- Executive change
  Praveen P. Tipirneni changed role as Chief Executive Officer at Morphic Holding, Inc..
  - Action: taking temporary medical leave of absence
  - Role: Chief Executive Officer
  source text: Praveen P. Tipirneni, M.D., the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), is taking a temporary medical leave of absence from his role as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.